UNSPSC 85813501: Introduction of other hormone into subcutaneous tissue, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of other hormone into subcutaneous tissue, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E013VJ

UNSPSC 85813501 Introduction of other hormone into subcutaneous tissue, percutaneous approach is a Commodity code with little relevant recent activity in state and local procurement. The code's clinical specificity—subcutaneous hormone injection procedures—does not map to the opportunities the source identifies under this tag. Recent opportunities instead cover virtual urgent care delivery, general medical services, cancer screening, employee health clinics, occupational health programs, EMS staffing, psychiatric evaluation, wellness platforms, and recovery services—none of which center on hormone injection administration or related pharmaceutical procedures. The issuing bodies include health plans (Inland Empire Health Plan in California), county health authorities (DeKalb County, Georgia; Nevada Health Authority), municipal health systems (San Mateo Medical Center, City of Ocala), county sheriffs' offices, state agencies, and regional health systems, reflecting typical state and local healthcare procurement. Geographic activity spans California, Georgia, Nevada, Florida, Colorado, Illinois, Texas, and New York.

The source shows no solicitations explicitly requesting hormone injection services, pharmaceutical administration training, or related clinical procedures under this code. One opportunity—Inland Empire Health Plan's Virtual Urgent Care Services RFI (due October 31, 2026)—involves telehealth evaluation and medication prescribing authority, but the scope encompasses general urgent care, not hormone therapy specifically. The mismatch between the code's narrow clinical definition and the breadth of general healthcare services tagged under it suggests either miscoding in the procurement databases or that the code does not reflect active state and local purchasing in this domain. Firms pursuing opportunities under this code should verify the actual clinical or pharmaceutical scope in full RFP documents before allocating business development resources, as the opportunities currently posted do not align with subcutaneous hormone injection services.